Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) price objective on Sanofi SA (EPA:SAN) in a research report report published on Monday. The brokerage currently has a neutral rating on the stock.

Several other analysts have also recently weighed in on the stock. Deutsche Bank AG set a €96.00 ($112.94) price target on shares of Sanofi SA and gave the company a buy rating in a report on Tuesday, August 1st. J P Morgan Chase & Co set a €90.00 ($105.88) price target on shares of Sanofi SA and gave the company a neutral rating in a report on Tuesday, August 1st. Sanford C. Bernstein set a €90.00 ($105.88) target price on shares of Sanofi SA and gave the company a neutral rating in a report on Monday, July 31st. Berenberg Bank set a €97.00 ($114.12) target price on shares of Sanofi SA and gave the company a neutral rating in a report on Monday, July 31st. Finally, S&P Global set a €90.00 ($105.88) target price on shares of Sanofi SA and gave the company a neutral rating in a report on Monday, July 31st. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company’s stock. Sanofi SA has an average rating of Hold and a consensus price target of €87.63 ($103.09).

Sanofi SA (SAN) opened at 80.80 on Monday. Sanofi SA has a 52 week low of €62.50 and a 52 week high of €92.97. The company has a market capitalization of €101.46 billion and a price-to-earnings ratio of 11.27. The company’s 50-day moving average is €25.48 and its 200 day moving average is €25.74.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/11/goldman-sachs-group-inc-the-analysts-give-sanofi-sa-epasan-a-82-00-price-target.html.

Sanofi SA Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.